LIMA-PERU - VIRTUAL 9-10 ZOOM STREAMING - Sociedad Peruana de Oncología Médica
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
LIMA-PERU
Foto: Pixabay
INFORMATION
Telephone:
997 930 727
JULY Mail:
spom@spomedica.org
ZOOM STREAMING
9-10 VIRTUAL VALIDACIÓN PARA
RECERTIFICACIÓN
MÉDICA
Estimados colegas:
La Sociedad Peruana de Oncología La confianza depositada por ASCO
Médica, como sociedad primaria (American Society of Clinical
tiene por principio la educación Oncology) y el trabajo realizado por
medica continua y la generación las gestiones previas, nos permiten
de conocimiento. continuar con el desarrollo de la
edición XII Best of ASCO, evento
En este tiempo inédito hemos científico que engloba los principales
aprendido que el conocimiento avances en prevención, diagnóstico,
científico independiente de las tratamiento, salud pública, políticas
diferentes modalidades, no se sanitarias, terapia de soporte entre
detiene y es la base de nuestro otros.
desarrollo como médicos y por lo
tanto la posibilidad de continuar Estamos seguros que en estos
laborando en beneficio de nuestros días nos enriqueceremos con la
pacientes y de nuestra sociedad. participación y experiencia de
ponentes y expertos nacionales e
La edición 56ta. de la Reunión de internacionales, por este motivo y
ASCO se ha caracterizado por a nombre de la Junta Directiva les
integrar el conocimiento y sobre damos la bienvenida a este
todo incentivar las relaciones prestigioso evento académico.
institucionales desde la accesibilidad,
desarrollo de nuevas drogas hasta
los programas de pacientes Silvia Neciosup Delgado MD
sobrevivientes. Spom President
BEST OF ASCO 2021
July 9
OPENNING 13:50-14:00 h
SILVIA NECIOSUP DELGADO MD
Presentador: Carlos Desposorio MD 14:00-14:35 h
GENITOURINARY CANCER-KIDNEY
AND BLADDER
Final analysis of KEYNOTE-426: Pembrolizumab plus axitinib versus sunitinib as
first-line therapy for advanced clear cell renal cell carcinoma (ccRCC).
Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of
lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus su-
nitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC):
Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma:
Results of a phase 2 trial.
Ray Manneh Kopp MD
VIDEO MSD
14:35-15:10 h
Presentadora: Zaida Morante MD
GENITOURINARY CANCER-PROSTATE,
TESTICULAR, AND PENILE
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus predniso-
ne and/or local radiotherapy in men with de novo metastatic castration-sensitive
prostate cancer (mCSPC): First results of PEACE-1.
Association of increased intensity of prostate-specific antigen screening in youn-
ger African American men with improved prostate cancer outcomes.
The CADMUS trial: A paired cohort, blinded study comparing multiparametric
ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the
detection of clinically significant prostate cancer.
Milagros Huaringa MDBEST OF ASCO 2021
VIDEO TECNOFARMA
Presentador: Miguel Ticona MD 15:10-15:35 h
SARCOMA
Treatment delays are associated with an unfavorable outcome in patients with
localized Ewing sarcoma: A retrospective analysis of data from the GPOH Eu-
ro-E.W.I.N.G.99 trial.
Eribulin and gemcitabine in previously treated patients with advanced liposarco-
ma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.
High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma
(ASPS) and other rare sarcoma histotypes.
Andrés Cardona MD
VIDEO BAYER
15:35-16:00 h
Presentador: Eduardo Nuñez MD
CENTRAL NERVOUS
SYSTEM TUMORS
Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papi-
llary craniopharyngiomas.
Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyo-
sin receptor kinase (TRK) fusion-positive primary central nervous system tumors
Long-term results of the GEINO 140 TRIAL: randomizing patients to stop or to
continue temozolomide until 12 cycles
Andrés Cardona MD
VIDEO ELI LILLYJULY 9
Presentadora: Denisse Castro MD 16:00-16:35 h
MELANOMA/SKIN CANCER
Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced mela-
noma: Primary phase 3 results from RELATIVITY-047 (CA224-047).
Crossover and rechallenge with pembrolizumab in recurrent patients from the
EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after
complete resection of high-risk stage III melanoma.
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab
(rela) for patients (pts) with resectable clinical stage III melanoma.
Teresa Puertolas MD
VIDEO BRISTOL MYERS SQUIBB
Presentadora: Denisse Castro MD 16:35-17:05 h
Symposium BRISTOL MYERS SQUIBB
LARGOS SUPERVIVIENTES CON LA
INMUNOTERAPIA INCLUSO EN
SITUACIONES DE MAL PRONÓSTICO
Teresa Puertolas MD
VIDEO PFIZER
Presentadora: Mivael Olivera MD 17:05-17:40 h
HEAD AND NECK CANCER
Camrelizumab versus placebo combined with gemcitabine and cisplatin for re-
current or metastatic nasopharyngeal carcinoma: A randomized, double-blind,
phase III trial.
Cabozantinib versus placebo in patients with radioiodine-refractory differentia-
ted thyroid cancer who have progressed after prior VEGFR-targeted therapy: Re-
sults from the phase 3 COSMIC-311 trial.
Metronomic capecitabine as adjuvant therapy in locoregionally advanced naso-
pharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
Ricard Mesia MDBEST OF ASCO 2021
VIDEO NOVARTIS
VIDEO EUROFARMA
Presentadora: Natalia Valdivieso MD 17:40-18:15 h
GYNECOLOGIC CANCER
Optimal treatment duration of bevacizumab (BEV) combined with carboplatin
and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian
tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized
2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO
(AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).
Intensive versus minimalist follow-up in patients treated for endometrial cancer:
A multicentric randomized controlled trial (The TOTEM study—NCT00916708).
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug
conjugate (ADC), in combination with bevacizumab in patients (pts) with plati-
num-agnostic ovarian cancer: Final analysis.
Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer:
Efficacy assessment of homologous recombination proficient (HRP) patients in
the phase IIb VITAL trial.
René Muñoz MD
VIDEO JANSSEN
VIDEO ROCHE
Presentadora: Luz Ventura MD 18:15-18:45 h
Symposium ROCHE
RELEVANCIA DEL MANEJO INTEGRAL DEL
CÁNCER DE PULMÓN Y SU IMPLEMENTACIÓN
A TRAVÉS DE LA MEDICINA DE PRECISIÓN
Santiago Ponce Aix MDJULY 9
VIDEO BIOTOSCANA
Presentadora: Luz Ventura MD 18:45-19:20 h
LUNG CANCER-NON-SMALL
CELL METASTATIC
Pooled analyses of immune-related adverse events (irAEs) and efficacy from the
phase 3 trials IMpower130, IMpower132, and IMpower150.
Racial disparities in biomarker testing and clinical trial enrollment in non-small
cell lung cancer (NSCLC).
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemothera-
py (chemo) versus chemo alone (4 cycles) in patients with advanced non-small
cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Amivantamab in combination with lazertinib for the treatment of osimertinib-re-
lapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer
(NSCLC) and potential biomarkers for response.
Carlos Carracedo MDBEST OF ASCO 2021
July 10
Presentador: Hugo Fuentes MD 8:00-8:35 h
BREAST CANCER-LOCAL/REGIONAL/ADJUVANT
Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.
Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase
Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42.
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel
weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and
survival results.
Miguel Martin MD
VIDEO ROCHE
Presentador: Hugo Fuentes MD 8:35-9:05 h
Symposium ROCHE
BLOQUEO DUAL EN CÁNCER DE MAMA HER2+:
INNOVACIÓN EN LA APLICACIÓN DEL TRATAMIENTO
Mauricio Burotto MD
VIDEO PFIZER
Presentador: Fernando Valencia MD 9:05-9:40 h
BREAST CANCER-METASTATIC
Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for
metastatic breast cancer with hormone receptor-positive and HER2-positive: The
sysucc-002 randomized clinical trial.
Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer
that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multi-
center, randomized, phase 3 study.
Treatment-related side effects and views about dosage assessment to sustain
quality of life: Results of an advocate-led survey of patients with metastatic breast
cancer (MBC).
Paula Cabrera MDJULY 10
VIDEO EUROFARMA
VIDEO NOVARTIS
Presentadores: Silvia Neciosup MD-Luis Schwarz MD 9:40-10:10 h
Symposium NOVARTIS
CÁNCER DE MAMA LUMINAL
Cristian Villanueva MD
VIDEO BAYER
Presentador: Daniel Enriquez MD 10:10-10:45 h
HEMATOLOGIC MALIGNANCIES-PLASMA
CELL DYSCRASIA-LMC
Daratumumab (DARA) maintenance or observation (OBS) after treatment with
bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and
autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed
multiple myeloma (NDMM): CASSIOPEIA Part 2.
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclo-
phosphamide-dexamethasone (KCd) consolidation with K maintenance in trans-
plant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).
OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponati-
nib (PON).
Elisa Quiroz MD
VIDEO JANSSENBEST OF ASCO 2021
Presentadora: Lourdes López MD 10:45-11:15 h
Symposium JANSSEN
ESTADO DEL ARTE ACTUAL EN EL MANEJO
DEL MM: RELEVANCIA DE LA ENFERMEDAD
MÍNIMA RESIDUAL Y ABORDAJE DE
ENFERMEDAD DE ALTO RIESGO
Angelo Maiolino MD
VIDEO BIOTOSCANA
Presentadora: Lourdes López MD 11:15-11:50 h
HEMATOLOGIC MALIGNANCIES-LEUKEMIA,
LYMPHOMA AND CLL
Effect of olutasidenib (FT-2102) on complete remissions in patients with relap-
sed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a plan-
ned interim analysis of a phase 2 clinical trial.
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously
treated chronic lymphocytic leukemia
Myeloablative vs non-myeloablative consolidative chemotherapy for newly diag-
nosed primary central nervous system lymphoma CALGB 51101 (Alliance)
CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin
lymphoma (cHL)
Jacqueline Barrientos MD
VIDEO ROCHE
VIDEO TECNOFARMAJULY 10
Presentador: Carlos Castañeda MD 11:50-12:15 h
DEVELOPMENTAL THERAPEUTICS-IMMUNOTHERAPY
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, sma-
ll-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts)
with unresectable or metastatic melanoma or advanced solid tumors that have
failed immuno-oncologic (I-O) drugs.
Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy
(C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
Sergio Santillana MD
VIDEO JANSSEN
Presentador: Carlos Castañeda MD 12:15-12:40 h
DEVELOPMENTAL THERAPEUTICS-MOLECULARLY
TARGETED AGENTS AND TUMOR BIOLOGY
MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of
a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tu-
mors.
A phase Ib trial of belvarafenib in combination with cobimetinib in patients with
advanced solid tumors: Interim results of dose-escalation and patients with
NRAS-mutant melanoma of dose-expansion.
Sergio Santillana MD
VIDEO MSD
Presentador: Carlos Aliaga MD 12:40-13:10 h
Symposium MSD
REDEFINIENDO LA SOBREVIDA DE
PACIENTES CON NSCLC
Carlos Barrios MDBEST OF ASCO 2021
VIDEO BRISTOL MYERS SQUIBB
Presentador: Carlos Aliaga MD 13:10-13:45 h
LUNG CANCER-NON-SMALL CELL
LOCAL-REGIONAL/SMALL CELL/OTHER
IMpower010: Primary results of a phase III global study of atezolizumab vs. best
supportive care after adjuvant chemotherapy in resected Stage IB-IIIA non-small
cell lung cancer (NSCLC).
Video-assisted thoracoscopic versus open lobectomy in patients with early-sta-
ge lung cancer: One-year results from a randomized controlled trial (VIOLET).
Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT)
with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LS-
CLC): CALGB 30610 (Alliance)/RTOG 0538.
A randomized phase II trial of oral vinorelbine as second-line therapy for patients
with malignant pleural mesothelioma.
Oscar Arrieta MD
VIDEO TECNOFARMA
Presentador: Cristian Pacheco MD 13:45-14:15 h
Symposium TECNOFARMA
IMPACTO DEL USO DE ANTIEGFR´S EN PRIMERA
LÍNEA DE TRATAMIENTO EN CÁNCER COLORRECTAL
METASTÁSICO RASWT
Alan Burguete Torres MD
VIDEO ELI LILLYJULY 10
Presentador: Cristian Pacheco MD 14:15-14:50 h
GASTROINTESTINAL CANCER-COLORECTAL
AND ANAL
Final overall survival for the phase 3 KN177 study: Pembrolizumab versus che-
motherapy in microsatellite instability-high/mismatch repair deficient metastatic
colorectal cancer.
Oral maintenance capecitabine versus active monitoring for patients with metas-
tatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of
first-line treatment: Results from the randomized FOCUS4-N trial.
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expres-
sing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicen-
ter, open-label study (DESTINY-CRC01).
The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus be-
vacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-li-
ne treatment in patients with metastatic colorectal cancer.
Erika Ruiz MD
VIDEO BRISTOL MYERS SQUIBB
Presentador: Frank Ruiz MD 14:50-15:20 h
Symposium BRISTOL MYERS SQUIBB
EL ROL DE LA INMUNOTERAPIA EN EL MANEJO
DEL CÁNCER GÁSTRICO AVANZADO
Juan Manuel O’Connor MD
VIDEO NOVARTISBEST OF ASCO 2021 | JULY 10
Presentador: Frank Ruiz MD 15:20-15:55 h
GASTROINTESTINAL CANCER-GASTROESOPHAGEAL,
PANCREATIC, AND HEPATOBILIARY
Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leuco-
vorin (LV) for patients with metastatic biliary tract cancer (BTC) after progres-
sion on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomi-
zed phase 2b study (NIFTY).
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction
cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded
efficacy and safety analyses from CheckMate 577.
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo)
versus chemo as first-line (1L) treatment for advanced esophageal squamous cell
carcinoma (ESCC): First results of the CheckMate 648 study.
Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus so-
rafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, ran-
domized, phase 3 trial (The FOHAIC-1 study).
Paola Montenegro MD
VIDEO BAYER
Presentadora: Gladys Giraldo MD 15:55-16:25 h
Symposium BAYER
EL DESAFÍO EN HEPATOCARCINOMA.
¿CÓMO NAVEGAR HACIA UNA SECUENCIACIÓN
ÓPTIMA DEL TRATAMIENTO?
Leonardo Da Fonseca MD
CLAUSURA 16:25-16:30 h
SILVIA NECIOSUP DELGADO MDSociedad Peruana de
Oncología Médica
Dra. Silvia Patricia Neciosup Delgado
Presidente
Dr. Alejandro Figueroa Torrejón
Vicepresidente
Dr. Hugo Alejandro Fuentes Rivera
Secretario general
Dra. Paola Montenegro Beltrán
Secretaria de acción científica
Dr. Carlos Desposorio Lozano
Secretario de finanzas
Dr. Oscar Carnero Fuentes
Secretario de filiales
Dra. Essy Maradiegue Chirinos
Vocal de actas
Dr. Marco Gálvez Villanueva
Vocal de ética, juicio y opiniónYou can also read
